TUSTIN, Calif., Oct. 3 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, today announced that the Company will present at the Maxim Group Growth Investor Conference in New York City on Tuesday, October 7, 2008 at 10:30 a.m. ET. AMDL's presentation will be held at the Grand Hyatt New York Hotel in the Morosco Room.
The Maxim Group Growth Conference features interactive presentations and one-on-one meetings with executives from over 80 emerging growth companies within various sectors including healthcare and pharmaceuticals. Attendees include securities analysts, fund managers and institutional investors.
AMDL, Inc. is a specialty pharmaceutical Company devoted to the research, development, manufacturing, and marketing of over 180 diagnostic, pharmaceutical, nutritional supplement, and cosmetic products in China and outlying markets.
This year alone, the Company has secured over $25 million in sales contracts for its best-selling Goodnak(R) anti-aging product; expanded the Goodnak(R) revenue opportunity with the launch of two additional product formulations that include Goodnak(R) capsules and Goodnak(R) lotions; and secured US FDA clearance on July 3, 2008 for its ELISA DR-70(R) FDP cancer diagnostic test - the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.
These are a few milestones AMDL's Board Chairman and Audit Committee
Chair Mr. Douglas MacLellan will highlight in a presentation which will
also cover AMDL's market opportunity as an aggressively growing micro-cap
investment opportunity in t
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved